| Literature DB >> 28222811 |
Antonella Frattari1, Giustino Parruti2, Rocco Erasmo3, Luigi Guerra3, Ennio Polilli2, Rosamaria Zocaro4, Giuliano Iervese4, Paolo Fazii5, Tullio Spina4.
Abstract
BACKGROUND: In critically ill patients with colonization/infection of multidrug-resistant organisms, source control surgery is one of the major determinants of clinical success. In more complex cases, the use of different tools for sepsis management may allow survival until complete source control. CASEEntities:
Keywords: Case report; Control surgery; Intensive assistance; Septic shock
Mesh:
Substances:
Year: 2017 PMID: 28222811 PMCID: PMC5320692 DOI: 10.1186/s13256-017-1206-6
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Overview of antimicrobial association treatments used in this patient
| Days of hospitalization in intensive care | Combination therapy | Doses | Microbiological data | Site of infection |
|---|---|---|---|---|
| 1–7 | Piperacillin/tazobactam | LD 4.5 gr + 4.5 gr/6 hour | Empirical regimen | Lung |
| 7–21 | Daptomycin | 8 mg/Kg (1 gr/day) | Blood cultures: | Pelvic insertion sites |
| 21–32 | Colimycin (colistin) | LD 9 MU + 4.5 MU/12 hour intravenous | Blood cultures: negative | Lung |
| 32–36 | Meropenem | 2 gr/8 hour | Blood cultures: | Intestine |
| 36–72 | Colimycin (colistin) | LD 9 MU + 4.5 MU/12 hour intravenous + | SeptiFast: | Bloodstream |
| 72–77 | Meropenem | 2 gr/8 hour | Wound swabs: | Surgical site |
| 77–132 | Colimycin (colistin) | LD 9 MU + 4.5 MU/12 hour | Surgical wounds and blood cultures: | Surgical site |
| 132–146 | Meropenem | 2 gr/6 hour | Rectal swab | Intestine Blood stream |
LD loading dose, KPC Klebsiella pneumoniae carbapenemase, MDR multidrug-resistant, MU million, panres panresistant
Fig. 1Pelvic fracture of the patient after the intervention of osteosynthesis
Fig. 2a Toraymyxin hemoperfusion scheme (duration 2 hours), as accessed at www.estor.it. b Coupled plasma filtration adsorption schematic diagram, as accessed at www.bellco.net. V. vein